Citius Oncology Inc (CTOR) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.47 is considered Undervalued compared with the five-year average of -0.95. The fair price of Citius Oncology Inc (CTOR) is between 3.35 to 5.63 according to relative valuation method. Compared to the current price of 1.08 USD , Citius Oncology Inc By Undervalued By 67.77%.

Relative Value

Fair Zone

3.35-5.63

Current Price：1.08

67.77%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Citius Oncology Inc (CTOR) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Citius Oncology Inc (CTOR) has a current Price-to-Book (P/B) ratio of 2.01. Compared to its 3-year average P/B ratio of 13.91, the current P/B ratio is approximately -85.54% higher. Relative to its 5-year average P/B ratio of 14.22, the current P/B ratio is about -85.87% higher. Citius Oncology Inc (CTOR) has a Forward Free Cash Flow (FCF) yield of approximately -6.00%. Compared to its 3-year average FCF yield of -0.28%, the current FCF yield is approximately 2051.29% lower. Relative to its 5-year average FCF yield of -0.26%, the current FCF yield is about 2193.36% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for CTOR competitors is 16.30, providing a benchmark for relative valuation. Citius Oncology Inc Corp (CTOR.O) exhibits a P/S ratio of 1.47, which is -91% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of CTOR increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of CTOR in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is CTOR currently overvalued or undervalued?

What is Citius Oncology Inc (CTOR) fair value?

CTOR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Citius Oncology Inc (CTOR) is between 3.35 to 5.63 according to relative valuation method.

How does CTOR's valuation metrics compare to the industry average?

The average P/S ratio for CTOR's competitors is 16.30, providing a benchmark for relative valuation. Citius Oncology Inc Corp (CTOR) exhibits a P/S ratio of 1.47, which is -91.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Citius Oncology Inc (CTOR) as of Mar 03 2026?

As of Mar 03 2026, Citius Oncology Inc (CTOR) has a P/B ratio of 2.01. This indicates that the market values CTOR at 2.01 times its book value.

What is the current FCF Yield for Citius Oncology Inc (CTOR) as of Mar 03 2026?

As of Mar 03 2026, Citius Oncology Inc (CTOR) has a FCF Yield of -6.00%. This means that for every dollar of Citius Oncology Inc's market capitalization, the company generates -6.00 cents in free cash flow.

What is the current Forward P/E ratio for Citius Oncology Inc (CTOR) as of Mar 03 2026?

As of Mar 03 2026, Citius Oncology Inc (CTOR) has a Forward P/E ratio of -7.71. This means the market is willing to pay $-7.71 for every dollar of Citius Oncology Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Citius Oncology Inc (CTOR) as of Mar 03 2026?

As of Mar 03 2026, Citius Oncology Inc (CTOR) has a Forward P/S ratio of 1.47. This means the market is valuing CTOR at $1.47 for every dollar of expected revenue over the next 12 months.

CTOR Valuation